Literature DB >> 18167620

The incidence of second primary invasive melanoma in Queensland, 1982-2003.

Kieran A McCaul1, Lin Fritschi, Peter Baade, Michael Coory.   

Abstract

OBJECTIVE: To describe the incidence of second primary invasive melanoma.
METHODS: Data describing 52,997 subjects with melanoma notified to The Queensland Cancer Registry between 1982 and 2003. We calculated incidence rates of second primary invasive melanoma (per 1,000 person-years) by sex, age, and characteristics of the first primary.
RESULTS: The rate of second primary invasive melanoma was relatively constant over 20 years of follow-up at 6.01 per 1,000 person-years indicating a high, constant lifetime risk of second primary invasive melanoma. Rates were 62% higher in males than in females and increased with age at first diagnosis with the rate in older patients (80+ years) more than double the rate observed in younger patients (40-49 years). Rates in patients with melanomas thicker than 2 mm were over 50% higher than in patients with thinner melanomas.
CONCLUSIONS: Melanoma patients are at high risk of a second primary invasive melanoma. This risk does not diminish with time and does not differ significantly between patients first diagnosed with lentigo maligna, in situ melanoma or invasive melanoma. These results indicate that all melanoma patients require lifetime surveillance. Current treatment guidelines should be modified to reflect this.

Entities:  

Mesh:

Year:  2008        PMID: 18167620     DOI: 10.1007/s10552-007-9106-5

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  4 in total

1.  Cutaneous melanoma in situ: translational evidence from a large population-based study.

Authors:  Simone Mocellin; Donato Nitti
Journal:  Oncologist       Date:  2011-05-31

2.  Nevi, family history, and fair skin increase the risk of second primary melanoma.

Authors:  Victor Siskind; Maria Celia B Hughes; Jane M Palmer; Judith M Symmons; Joanne F Aitken; Nicholas G Martin; Nicholas K Hayward; David C Whiteman
Journal:  J Invest Dermatol       Date:  2010-10-14       Impact factor: 8.551

3.  Multiple Primary Melanomas: Retrospective Review in a Tertiary Care Hospital.

Authors:  Rodolfo David Palacios-Diaz; Blanca de Unamuno-Bustos; Carlos Abril-Pérez; Mónica Pozuelo-Ruiz; Javier Sánchez-Arraez; Ignacio Torres-Navarro; Rafael Botella-Estrada
Journal:  J Clin Med       Date:  2022-04-22       Impact factor: 4.964

4.  Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma.

Authors:  Thomas E Pennington; Cathy Yunjia Zhao; Andrew J Colebatch; Pablo Fernandez-Peñas; Pascale Guitera; Hazel Burke; Richard A Scolyer; Alexander M Menzies; Matteo S Carlino; Serigne Lo; Georgina V Long; Robyn Pm Saw
Journal:  Australas J Dermatol       Date:  2022-02-21       Impact factor: 2.481

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.